JP MORGAN/CALL/VERTEX PHARMACEUTICALS/435/0.1/17.01.25 | Market Closed - Börse Stuttgart 10:20:09 20/06/2024 BST | ||
| 6.51 EUR | +1.88% |
|
| Current month | +25.92% | ||
| 1 month | +20.11% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 6.51 | +1.88% |
| 19/06/24 | 6.39 | -7.79% |
| 18/06/24 | 6.93 | -5.84% |
| 17/06/24 | 7.36 | -1.60% |
| 14/06/24 | 7.48 | +7.78% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 10:20 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL2HN7 |
| ISIN | DE000JL2HN72 |
| Date issued | 02/05/2023 |
| Strike | 435 $ |
| Maturity | 17/01/2025 (211 Days) |
| Parity | 10 : 1 |
| Emission price | 2.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.85 € |
|---|---|
| Lowest since issue | 2.33 € |
| Spread | 0.3 € |
| Spread % | 4.27% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
471.4
USD
Average target price
463.4
USD
Spread / Average Target
-1.69%
- Stock Market
- Warrants
- Warrant
